GlassScriptPhysician profile
Chelsi Davis
NPI 1225692098
$6,559.22
in general payments reported to CMS, 2019-2025
22 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,089 · 2022: $406 · 2023: $2,035 · 2024: $1,046 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,242 · Consulting Fee: $750 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,241.85 |
| Consulting Fee | $750.00 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.46 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $768.01 | 2023 | |
| Novartis Pharmaceuticals Corporation | $617.02 | 2021-2025 | |
| Dermavant Sciences, INC. | $572.75 | 2023-2024 | Vtama |
| Genzyme Corporation | $538.77 | 2021-2025 | |
| Incyte Corporation | $357.75 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $322.06 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $293.38 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $276.67 | 2021-2023 | Duobrii, Jublia, Arazlo |
| Regeneron Healthcare Solutions, INC. | $269.72 | 2021-2025 | Dupixent |
| Ucb, INC. | $211.79 | 2024-2025 | Bimzelx |
| Organon LLC | $192.96 | 2025 | Vtama |
| Janssen Biotech, INC. | $191.47 | 2023-2025 | Tremfya |
| Amgen INC. | $189.99 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $155.32 | 2021-2025 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $96.02 | 2021-2025 | |
| Galderma Laboratories, L.P. | $91.25 | 2022-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $77.49 | 2023-2025 | |
| Organogenesis INC. | $76.36 | 2023 | Puraply |
| Vyne Pharmaceuticals INC. | $30.78 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.90 | 2023 | Nuzyra |
| Journey Medical Corporation | $15.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsi Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.